Untargeted Metabolomics Identifies a Novel Panel of Markers for Autologous Blood Transfusion

Untargeted metabolomics was used to analyze serum and urine samples for biomarkers of autologous blood transfusion (ABT). Red blood cell concentrates from donated blood were stored for 35−36 days prior to reinfusion into the donors. Participants were sampled at different time points post-donation an...

Full description

Saved in:
Bibliographic Details
Published in:Metabolites 2022-05, Vol.12 (5), p.425
Main Authors: Al-Nesf, Amna, Mohamed-Ali, Nada, Acquaah, Vanessa, Al-Jaber, Maneera, Al-Nesf, Maryam, Yassin, Mohamed A, Orie, Nelson N, Voss, Sven Christian, Georgakopoulos, Costas, Bhatt, Rikesh, Beotra, Alka, Mohamed-Ali, Vidya, Al-Maadheed, Mohammed
Format: Article
Language:English
Subjects:
autologous transfusion
biomarker
Biomarkers
Blood & organ donations
Blood transfusion
Blood transfusions
Erythrocytes
Glutamine
Hemoglobin
Hypotheses
Investigations
Ionization
Liquid chromatography
Metabolites
Metabolomics
Principal components analysis
Sphinganine
untargeted metabolomics
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Untargeted metabolomics was used to analyze serum and urine samples for biomarkers of autologous blood transfusion (ABT). Red blood cell concentrates from donated blood were stored for 35−36 days prior to reinfusion into the donors. Participants were sampled at different time points post-donation and up to 7 days post-transfusion. Metabolomic profiling was performed using ACQUITY ultra performance liquid chromatography (UPLC), Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The markers of ABT were determined by principal component analysis and metabolites that had p < 0.05 and met ≥ 2-fold change from baseline were selected. A total of 11 serum and eight urinary metabolites, including two urinary plasticizer metabolites, were altered during the study. By the seventh day post-transfusion, the plasticizers had returned to baseline, while changes in nine other metabolites (seven serum and two urinary) remained. Five of these metabolites (serum inosine, guanosine and sphinganine and urinary isocitrate and erythronate) were upregulated, while serum glycourdeoxycholate, S-allylcysteine, 17-alphahydroxypregnenalone 3 and Glutamine conjugate of C6H10O2 (2)* were downregulated. This is the first study to identify a panel of metabolites, from serum and urine, as markers of ABT. Once independently validated, it could be universally adopted to detect ABT.
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo12050425